CAFC Reverses $9.1 Million Exceptionality Award, Holding Myriad Did Not Foreclose Patent Owner’s 101 Argument

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Friday reversed a district court’s award of attorneys’ fees to Elysium Health, Inc., holding that the lower court erred in assessing the substantive strength of ChromaDex’s Section 101 position. The appeal is rooted in the CAFC’s 2023 decision affirming the U.S. District Court for the District of Delaware’s grant of summary judgment for Elysium Health that the asserted claims of ChromaDex’s patent on an isolated form of vitamin B3 were